Anatara Lifesciences Ltd (ASX:ANR) Receives Ethics Approval to Start IBS Trial
Anatara Receives Ethics Approval to Start IBS TrialMelbourne, Feb 8, 2021 AEST (ABN Newswire) - Anatara Lifesciences (
ASX:ANR) is pleased to advise that it is has received Human Research Ethics Committee (HREC) approval to undertake a clinical trial of its Gastrointestinal Re-Programming complementary medicine (GaRP) in participants with irritable bowel syndrome - diarrhoea subtype (IBS-D).
Highlights:
- Study design is Randomised, Double-Blinded and Placebo-Controlled to address future evidence-based claims
- Virtual study with ObvioHealth Australia to provide digital clinical trial platform ClaimIt
- Supported by leading CROs: GenesisCare Clinical CRO, Microba, Sonic Clinical Trials